Original Research Article I Volume 8 I Issue 2 I 2020

Comparative Study Between Vaginal Natural Progesterone and Oral Dydrogesterone in Prevention of Red Degeneration of Uterine Fibroid in Pregnancy

Nermeen M. Hefila, Tarek A. Karkour, Sarah M. Elghareeb, Tamer M. Abdeldaiem

Biolife; 2020, 8(2), pp 10-14

DOI:https://doi.org/10.5281/zenodo.7404559

Abstract:

Uterine leiomyomas are highly prevalent benign monoclonal tumors, arising from the smooth muscle of the myometrium; they occur in up to 50-60% of reproductive age women, causing significant morbidity in up to 30% of women. The most serious complication of uterine fibroids; is red degeneration that causes severe pain, and may lead to preterm labour, miscarriage, fetal and maternal morbidity and mortality.

Keywords:

Vaginal Natural Progesterone -Oral Dydrogesterone -Red Degeneration - Pregnancy.

References:

 

  1. Okolo S. Incidence, etiology and epidemiology of uterine fibroids. Best Pract Res ClinObstetGynaecol 2008;22(4):571-88.
  2. Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health 2014;6:95-114.
  3. Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed Müllerian tumors of the uterus. Mod Pathol 2000;13(3):328–42.
  4. Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health 2012;12:6.
  5. Lee HJ, Norwitz ER, Shaw J. Contemporary Management of Fibroids in Pregnanc. Rev ObstetGynecol 2010;3(1):20-7.
  6. Han SC, Kim MD, Jung DC, Lee M, Lee MS, Park SI, et al. Degeneration of leiomyoma in patients referred for uterine fibroid embolization: incidence, imaging features and clinical characteristics. Yonsei Med J 2013;54(1):215-9.
  7. Simms-Stewart D, Fletcher H. Counselling patients with uterine fibroids: a review of the management and complications. ObstetGynecolInt 2012;2012:539365.
  8. Di Renzo Gc, Giardina I, Clerici G, Brillo E, Gerli S. Progesterone in normal and pathological pregnancy. HormMolBiolClinInvestig 2016;27(1):35-48.
  9. Dante G, Vaccaro V, Facchinetti F. Use of progestagens during early pregnancy. Facts Views Vis Obgyn 2013;5(1):66-71.
  10. Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial. Iran J Reprod Med 2013;11(11):913–8.
  11. Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 2009;65 Suppl 1:S3-11.
  12. Sahana Gupta, Isaac T. Manyonda, Acute complications of fibroids. Best Pract Res ClinObstetGynaecol 2009;23(5):609-17.....

Article Dates:

Received: 26 April, 2020; Accepted: 1 June 2020; Published: 21 June 2020

How To Cite:

Nermeen M. Hefila, Tarek A. Karkour, Sarah M. Elghareeb, & Tamer M. Abdeldaiem. (2022). Comparative Study Between Vaginal Natural Progesterone and Oral Dydrogesterone in Prevention of Red Degeneration of Uterine Fibroid in Pregnancy. Biolife, 8(2), 10–14. https://doi.org/10.5281/zenodo.7404559

Download Full Paper: PDF
Submit Manuscript
Join as Reviewer / Editor

Logo


Logo